Blurbs

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Ascendis Pharma (ASND) and Apellis Pharmaceuticals (APLS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Argenx Se (ARGXResearch Report), Ascendis Pharma (ASNDResearch Report) and Apellis Pharmaceuticals (APLSResearch Report).

Argenx Se (ARGX)

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Argenx Se today and set a price target of $278.00. The company’s shares closed last Monday at $267.39.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 9.8% and a 52.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $373.46, which is a 40.0% upside from current levels. In a report issued on March 3, Credit Suisse also maintained a Hold rating on the stock with a $319.00 price target.

See today’s best-performing stocks on TipRanks >>

Ascendis Pharma (ASND)

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Ascendis Pharma, with a price target of $180.00. The company’s shares closed last Monday at $104.01, close to its 52-week low of $102.00.

According to TipRanks.com, Purohit ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -30.5% and a 9.4% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Foghorn Therapeutics, and Theravance Biopharma.

Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $162.75, representing a 56.4% upside. In a report issued on February 28, Citigroup also initiated coverage with a Buy rating on the stock with a $187.00 price target.

Apellis Pharmaceuticals (APLS)

In a report released today, Madhu Kumar from Goldman Sachs maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $86.00. The company’s shares closed last Monday at $43.25.

According to TipRanks.com, Kumar is a 5-star analyst with an average return of 18.0% and a 47.3% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Arrowhead Pharmaceuticals, and Arvinas Holding Company.

Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $92.25, representing an 110.9% upside. In a report issued on March 1, Raymond James also maintained a Buy rating on the stock with a $114.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARGX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos